Abivax S.A. (0RA9.L) LSE

77.60

+6.7(+9.45%)

Updated at September 08 11:33AM

Currency In EUR

Abivax S.A.

Address

5, rue de la Baume

Paris, 75008

France

Phone

33 1 53 83 08 41

Sector

Healthcare

Industry

Medical - Pharmaceuticals

Employees

69

First IPO Date

September 30, 2016

Key Executives

NameTitlePayYear Born
Mr. Marc M. P. de Garidel M.B.A.Chief Executive Officer & Director630,9421958
Mr. Jerome Denis Ph.D.Executive Vice President of Process Development & Manufacturing0N/A
Mr. Patrick MalloySenior Vice President of Investor Relations0N/A
Ms. Ida HatoumChief People & Compliance Officer01975
Mr. Didier Scherrer Ph.D.Chief Scientific Officer01970
Mr. Didier BlondelEVice President, Chief Financial Officer & Board Secretary01964
Mr. Pierre Courteille M.B.A.Chief Business Officer01969
Hema KeshavaSenior Vice President of Finance0N/A
Chris Rabbat Ph.D.Vice President & Global Head of Medical Affairs0N/A
Kevin Shan Ph.D.Vice President & Global Head of Biometrics0N/A

Description

ABIVAX Société Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV. It also develops ABX 196, an immune enhancer candidate that is in Phase 1/2 clinical trials for the treatment of hepatocellular cancer. In addition, the company engages in the research programs for the treatment of Dengue fever, influenza, and respiratory syncytial virus. ABIVAX Société Anonyme has license contracts with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. The company was incorporated in 2013 and is headquartered in Paris, France.